Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MWN109 in Healthy Chinese Volunteers
NCT07787624Phase 1Completed
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd.
- Start
- Dec 2024
- Primary completion
- Jul 2025
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MWN109 in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by Shanghai Minwei Biotechnology Co., Ltd. Primary endpoint: Incidence of adverse events at Day 43. Started Dec 2024; status: completed.
02
Drugs
MWN109
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT07787624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07787624.